Enrique M. Ocio

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 620 citations

Hematological Malignancy, Medicine, Immunology +6

International prognostic scoring system for Waldenström macroglobulinemia

Pierre Morel, Alain Duhamel, Paolo G. Gobbi et al. · Blood · 2009 · 404 citations · Full text

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis et al. · Leukemia · 2017 · 348 citations · Full text

Hematological Malignancy, Proteasome Inhibitors, Relapsed Myeloma +10

The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes

Soraya Tabera, Josè Antonio Pérez-Simón, María Díez‐Campelo et al. · Haematologica · 2008 · 274 citations · Full text